We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+16.34%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.75B
AUM Growth
+$551M
Cap. Flow
+$76.2M
Cap. Flow %
1.6%
Top 10 Hldgs %
42.9%
Holding
172
New
17
Increased
41
Reduced
66
Closed
24

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$190M
2
INSM icon
Insmed
INSM
+$168M
3
GILD icon
Gilead Sciences
GILD
+$130M
4
UTHR icon
United Therapeutics
UTHR
+$105M
5
BBIO icon
BridgeBio Pharma
BBIO
+$81.5M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$121M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$82.6M
3
RVMD icon
Revolution Medicines
RVMD
+$72.5M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$70.4M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$63.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Technology 0.03%
3 Communication Services 0.01%
4 Consumer Discretionary 0.01%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
76
Protagonist Therapeutics
PTGX
$9.99B
$6.83M 0.14%
55,682
+41,235
+285% +$4.31M
NTRA icon
77
Natera
NTRA
$44.7B
$6.73M 0.14%
24,806
-6,888
-22% -$1.47M
TMDX icon
78
Transmedics
TMDX
$3.05B
$6.72M 0.14%
101,139
– –
MOH icon
79
Molina Healthcare
MOH
$11.2B
$6.35M 0.13%
+27,761
New +$5.03M
ALKS icon
80
Alkermes
ALKS
$8.27B
$6.3M 0.13%
120,243
+111,373
+1,256% +$4.35M
RPRX icon
81
Royalty Pharma
RPRX
$26.1B
$6.3M 0.13%
112,311
+74,015
+193% +$3.85M
WAY
82
Waystar Holding Corp
WAY
$4.76B
$6.03M 0.13%
293,592
+37,453
+15% +$788K
PRVA icon
83
Privia Health
PRVA
$2.82B
$5.83M 0.12%
226,703
– –
GMRS
84
GMR Solutions Inc
GMRS
$740M
$5.15M 0.11%
+333,333
New +$4.18M
NBIX icon
85
Neurocrine Biosciences
NBIX
$15.5B
$4.05M 0.09%
24,037
+19,391
+417% +$2.88M
OMDA
86
Omada Health Inc
OMDA
$1.46B
$3.47M 0.07%
157,938
– –
KMTS
87
Kestra Medical Technologies
KMTS
$1.64B
$3.29M 0.07%
129,215
+13,625
+12% +$285K
MDLN
88
Medline Inc
MDLN
$31.3B
$3.24M 0.07%
82,153
-54,482
-40% -$2.2M
ILMN icon
89
Illumina
ILMN
$29B
$3.19M 0.07%
18,134
-2,089
-10% -$306K
ONC
90
BeOne Medicines Ltd
ONC
$39.3B
$2.98M 0.06%
10,474
+6,662
+175% +$1.96M
NAMS icon
91
NewAmsterdam Pharma
NAMS
$3.2B
$2.95M 0.06%
86,994
+59,333
+215% +$1.96M
MDGL icon
92
Madrigal Pharmaceuticals
MDGL
$11.7B
$2.51M 0.05%
4,675
+1,635
+54% +$838K
SPY icon
93
State Street SPDR S&P 500 ETF Trust
SPY
$813B
$2.02M 0.04%
2,700
– –
BNTX icon
94
BioNTech
BNTX
$23.4B
$1.98M 0.04%
21,229
+378
+2% +$35.6K
ADPT icon
95
Adaptive Biotechnologies
ADPT
$3.94B
$1.92M 0.04%
89,439
+13,258
+17% +$203K
CYTK icon
96
Cytokinetics
CYTK
$10.3B
$1.62M 0.03%
19,007
+10,166
+115% +$730K
ALMR
97
Alamar Biosciences
ALMR
$2.26B
$1.51M 0.03%
+55,738
New +$1.26M
PHR icon
98
Phreesia
PHR
$762M
$1.45M 0.03%
140,495
+9,503
+7% +$88.2K
MOBI
99
Mobia Medical
MOBI
$391M
$1.34M 0.03%
+100,000
New +$1.29M
BLLN
100
BillionToOne Inc
BLLN
$4.41B
$1.27M 0.03%
10,554
– –
2 3
4
5 6

Similar funds

SAMU
SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

Bellevue Group's Q2 2026 Portfolio in Review

As of Q2 2026, Bellevue Group held 172 positions worth $4.75B, up 13% from $4.2B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Bellevue Group's Q2 2026 filing shows 17 new, 41 increased, 66 reduced and 24 closed positions. Its largest new stake was Avalyn Pharma: 1,350,000 shares worth $44.4M. The largest sale was Krystal Biotech, an estimated $121M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Communication Services.

  • Bellevue Group's largest Q2 2026 buy was Avalyn Pharma: 1,350,000 shares worth $44.4M.
  • Bellevue Group added most to Amgen in Q2 2026, an estimated $190M increase.
  • Bellevue Group's biggest Q2 2026 reduction was Krystal Biotech, cutting an estimated $121M.
  • Bellevue Group fully exited Edgewise Therapeutics in Q2 2026, selling an estimated $48.1M.
  • Bellevue Group's ten largest holdings make up 43% of its $4.75B portfolio in Q2 2026.
  • Bellevue Group opened 17 new positions and closed 24 in Q2 2026.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $4.75B.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.